JonesTrading Initiates Coverage on Relay Therapeutics

Analysts set a 'hold' rating and $18 price target on the biotech stock.

Apr. 14, 2026 at 12:23pm

Got story updates? Submit your updates here. ›

An extreme close-up of a complex array of metallic gears, cogs, and machinery, representing the intricate computational and experimental processes behind Relay Therapeutics' innovative drug discovery platform.Relay Therapeutics leverages advanced computational modeling and structural biology to identify promising drug candidates for hard-to-treat cancers.Cambridge Today

Equities research analysts at JonesTrading assumed coverage on shares of Relay Therapeutics (NASDAQ:RLAY) in a research note issued on Tuesday. The brokerage set a "hold" rating and a $18.00 price target on the stock, indicating a potential upside of 17.96% from the stock's current price.

Why it matters

Relay Therapeutics is a clinical-stage biotech company focused on developing precision therapies for cancer. The JonesTrading coverage initiation provides an independent assessment of the company's prospects and valuation from a respected Wall Street research firm.

The details

Other analysts have also weighed in on Relay Therapeutics, with Barclays, Weiss Ratings, Citizens Jmp, and Oppenheimer all issuing ratings and price targets on the stock in recent months. The consensus among analysts is a 'Moderate Buy' rating with an average price target of $18.38.

  • JonesTrading initiated coverage on Relay Therapeutics on Tuesday, April 14, 2026.

The players

JonesTrading

A full-service institutional brokerage firm that provides equity research coverage on Relay Therapeutics.

Relay Therapeutics

A clinical-stage biotechnology company focused on developing precision therapies for cancer using computational modeling, structural biology, and experimental validation.

Got photos? Submit your photos here. ›

What’s next

Investors will be watching to see if Relay Therapeutics can meet or exceed the $18 price target set by JonesTrading. The company's progress in advancing its pipeline of precision cancer therapies will also be closely monitored.

The takeaway

The JonesTrading coverage initiation provides an independent Wall Street perspective on Relay Therapeutics, which is developing an innovative approach to cancer drug discovery. While analysts see potential upside, the 'hold' rating suggests more cautious near-term expectations for the stock.